| | Business Summary | | EchoCath,
Inc.
is
engaged
in
developing,
manufacturing
and
marketing
medical
devices
that
enhance
and
expand
the
use
of
ultrasound
technology
for
medical
applications
and
procedures.
The
Company
has
developed
four
proprietary
ultrasound
technologies
comprised
of
one
that
characterizes
blood
flow,
two
that
enable
ultrasound
imaging
to,
among
other
things,
identify
devices
during
interventional
procedures
such
as
needle
biopsies
and
catheterizations,
and
one
that
provides
intraluminal
imaging.
The
Company's
technologies
include
EchoFlow,
a
proprietary
transcutaneous,
epivascular
and
catheter-based
sensor
and
electronics
system,
EchoMark,
a
catheter
positioning
system,
ColorMark,
which
highlights
metallic
objects
in
color
to
permit
them
to
be
easily
seen
on
existing
ultrasound
imaging
screens,
and
EchoEye,
a
proprietary
imaging
system. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | EchoCath,
Inc.
is
engaged
in
developing,
manufacturing,
and
marketing
medical
devices
which
enhance
and
expand
the
use
of
ultrasound
technology
for
medical
applications
and
procedures.
For
the
nine
months
ended
5/01,
revenues
totalled
$355
thousand,
up
from
$114
thousand.
Net
loss
applicable
to
Common
increased
3%
to
$1.8
million.
Revenues
reflect
an
increase
in
royalty
fees.
Higher
loss
reflects
increased
research
and
development
expenses. | | More
from
Market Guide: Significant
Developments |
| | Officers | | | FY2000 Pay | |
| Daniel Mulvena, 52
Chairman | -- | Frank DeBernardis, 57
Pres,
CEO | $130K | David Vilkomerson, Ph.D, 59
Exec.
VP, Director of Research and | 141K | Edwin Morton
VP of Sales and Marketing | -- | Irwin Rosenthal, 71
Sec. | -- | | Dollar
amounts are as of 31-Aug-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/e/echta.ob.gif)